Total Payments
$10,933
2024 Payments
$1,803
Companies
80
Transactions
557
Medicare Patients
6,831
Medicare Billing
$689,609
Payment Breakdown by Category
Food & Beverage$9,573 (87.6%)
Consulting$780.00 (7.1%)
Education$580.08 (5.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,573 | 536 | 87.6% |
| Consulting Fee | $780.00 | 1 | 7.1% |
| Education | $580.08 | 20 | 5.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $1,112 | 17 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,000 | 66 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $778.29 | 47 | $0 (2024) |
| Celgene Corporation | $535.59 | 25 | $0 (2024) |
| PFIZER INC. | $488.09 | 37 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $477.87 | 29 | $0 (2024) |
| Amgen Inc. | $446.99 | 25 | $0 (2023) |
| Astellas Pharma US Inc | $406.24 | 20 | $0 (2024) |
| Sirtex Medical Inc | $372.66 | 2 | $0 (2024) |
| Merck Sharp & Dohme LLC | $358.38 | 23 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,803 | 81 | AstraZeneca Pharmaceuticals LP ($135.02) |
| 2023 | $1,516 | 66 | Myriad Genetic Laboratories, Inc. ($184.99) |
| 2022 | $1,052 | 11 | Janssen Biotech, Inc. ($800.16) |
| 2021 | $280.05 | 3 | Sirtex Medical Inc ($254.27) |
| 2020 | $616.78 | 32 | E.R. Squibb & Sons, L.L.C. ($141.17) |
| 2019 | $2,217 | 137 | E.R. Squibb & Sons, L.L.C. ($244.20) |
| 2018 | $1,857 | 116 | E.R. Squibb & Sons, L.L.C. ($235.81) |
| 2017 | $1,590 | 111 | E.R. Squibb & Sons, L.L.C. ($188.98) |
All Payment Transactions
557 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $27.07 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/16/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $31.12 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $24.41 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $16.32 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/21/2024 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | In-kind items and services | $17.57 | General |
| Category: Hematology | ||||||
| 11/19/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $33.58 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $23.19 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $21.10 | General |
| Category: Oncology | ||||||
| 10/28/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $18.70 | General |
| Category: ONCOLOGY | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $22.61 | General |
| Category: Oncology | ||||||
| 10/21/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: ONCOLOGY | ||||||
| 10/07/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $15.67 | General |
| Category: Hematology | ||||||
| 10/02/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $19.84 | General |
| 09/24/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $19.08 | General |
| Category: Oncology | ||||||
| 09/23/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $19.60 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $34.34 | General |
| Category: ONCOLOGY | ||||||
| 09/09/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $23.58 | General |
| Category: Oncology | ||||||
| 09/09/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $15.96 | General |
| Category: HORMONE THERAPY | ||||||
| 09/05/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $19.75 | General |
| Category: Oncology | ||||||
| 09/03/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $30.83 | General |
| Category: Oncology | ||||||
| 08/29/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $22.25 | General |
| Category: ONCOLOGY | ||||||
| 08/26/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Education | In-kind items and services | $17.02 | General |
| Category: ONCOLOGY | ||||||
| 08/26/2024 | Kyowa Kirin, Inc. | Poteligeo (Drug) | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: Monoclonal Antibody | ||||||
| 08/21/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $19.67 | General |
| Category: Oncology | ||||||
| 08/12/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $27.07 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 1,943 | 44,921 | $731,980 | $150,850 |
| 2022 | 21 | 1,201 | 18,732 | $491,051 | $112,442 |
| 2021 | 25 | 1,583 | 60,762 | $663,292 | $183,510 |
| 2020 | 34 | 2,104 | 55,435 | $887,587 | $242,807 |
Total Patients
6,831
Total Services
179,850
Medicare Billing
$689,609
Procedure Codes
106
All Medicare Procedures & Services
106 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 385 | 563 | $155,951 | $34,930 | 22.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 119 | 184 | $71,760 | $16,940 | 23.6% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 38 | 33,660 | $134,640 | $13,456 | 10.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 41 | 131 | $55,151 | $12,402 | 22.5% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 31 | 160 | $33,600 | $11,329 | 33.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 479 | 1,054 | $30,566 | $7,991 | 26.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 67 | 67 | $34,103 | $7,486 | 22.0% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 12 | 1,200 | $30,000 | $7,159 | 23.9% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 14 | 4,680 | $28,080 | $6,418 | 22.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 68 | 137 | $28,496 | $6,336 | 22.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 50 | 95 | $20,330 | $5,786 | 28.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 70 | 261 | $26,883 | $5,414 | 20.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 21 | 22 | $13,090 | $2,804 | 21.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 241 | 318 | $2,862 | $2,665 | 93.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 25 | 26 | $10,556 | $2,606 | 24.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 12 | 43 | $8,815 | $1,934 | 21.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 48 | 193 | $12,931 | $1,854 | 14.3% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 14 | 38 | $6,840 | $1,395 | 20.4% |
| 96523 | Irrigation of implanted venous access drug delivery device | Office | 2023 | 20 | 33 | $2,739 | $575.05 | 21.0% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 18 | 470 | $19,270 | $379.49 | 2.0% |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | Office | 2023 | 42 | 85 | $1,105 | $263.67 | 23.9% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 17 | 21 | $1,386 | $240.01 | 17.3% |
| 85045 | Red blood count, automated test | Office | 2023 | 38 | 40 | $480.00 | $156.40 | 32.6% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 26 | 141 | $846.00 | $153.63 | 18.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 28 | 1,232 | $1,232 | $120.16 | 9.8% |
About Dr. Patrick Litam, MD
Dr. Patrick Litam, MD is a Hematology & Oncology healthcare provider based in Elyria, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1447203054.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patrick Litam, MD has received a total of $10,933 in payments from pharmaceutical and medical device companies, with $1,803 received in 2024. These payments were reported across 557 transactions from 80 companies. The most common payment nature is "Food and Beverage" ($9,573).
As a Medicare-enrolled provider, Litam has provided services to 6,831 Medicare beneficiaries, totaling 179,850 services with total Medicare billing of $689,609. Data is available for 4 years (2020–2023), covering 106 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Elyria, OH
- Active Since 05/18/2006
- Last Updated 01/10/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1447203054
Products in Payments
- RYBREVANT (Drug) $822.31
- OPDIVO (Biological) $814.40
- SIR-Spheres Microspheres (Device) $372.66
- KEYTRUDA (Biological) $345.90
- Revlimid (Drug) $275.76
- Imbruvica (Drug) $237.67
- JAKAFI (Drug) $222.65
- XTANDI (Drug) $221.22
- Neulasta (Biological) $197.53
- MYRISK (Device) $184.99
- IMBRUVICA (Drug) $172.77
- ADCETRIS (Biological) $158.02
- LIBTAYO (Biological) $154.75
- IBRANCE (Drug) $152.72
- CALQUENCE (Drug) $146.36
- ELIQUIS (Drug) $145.69
- SOLIRIS (Drug) $140.04
- VERZENIO (Drug) $129.21
- ALIMTA (Drug) $127.44
- KISQALI (Drug) $119.28
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.